Latest Breaking News On - Gastroesophageal junction - Page 3 : comparemela.com

FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma

The approval makes pembrolizumab the first-line treatment for individuals with this cancer.

FDA Approves PD-L1 IHC 22C3 to Identify Gastric or Gastroesophageal Junction Adenocarcinoma

The approval marks the sixth cancer type PD-L1 IHC 22C3 pharmDx has been granted, and the first for GEJ

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® using PD-L1 IHC 22C3 pharmDx .

Agilent (A) Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction Adenocarcinoma

Agilent Technologies, Inc. announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal.